HutchMed announces NMPA approval of surufatinib (Sulanda in China) for advanced pancreatic neuroendocrine tumours

18 June 2021 - Second new drug application approved for Sulanda in China. ...

Read more →

BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in microsatellite instability-high or mismatch repair-deficient solid tumours

7 June 2021 -BeiGene today announced that the Center for Drug Evaluation of the China NMPA has accepted a supplemental ...

Read more →

China NMPA approves PARP inhibitor pamiparib for patients with previously treated advanced ovarian cancer

7 May 2021 - This marks the first approval of pamiparib and the third BeiGene discovered medicine to receive regulatory approval. ...

Read more →

Citrine Medicine and Sinopharm Group announce strategic partnership to broaden and accelerate access to rare disease drugs in China

19 April 2021 - Citrine Medicine and Sinopharm Group today announced a strategic partnership to accelerate the commercialisation of rare ...

Read more →

Tagrisso approved in China in early lung cancer

14 April 2021 - Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk ...

Read more →

Qilian International announces inclusion of 16 products into China's National Reimbursement Drugs List

13 April 2021 - Qilian International today announced that 16 of its products have been included in the latest version of ...

Read more →

NMPA approves toripalimab in patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neo-adjuvant or adjuvant platinum-containing chemotherapy

12 April 2021 - Third indication approved for toripalimab in China. ...

Read more →

BeyondSpring announces submission of new drug application to U.S. FDA and China NMPA for plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia

31 March 2021 - Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers ...

Read more →

CStone announces China NMPA new drug approval of precision therapy Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA exon 18 mutant gastro-intestinal stromal tumour

31 March 2021 - Ayvakit is China’s first approved precision therapy for patients with PDGFRA exon 18 mutant gastro-intestinal stromal tumour. ...

Read more →

CStone announces new drug approval of Gavreto (pralsetinib) as first selective RET inhibitor in China, providing a new therapy for a subset of non-small cell lung cancer patients

24 March 2021 - Gavreto is the first approved selective RET inhibitor in China and first approved precision therapy for CStone. ...

Read more →

Everest Medicines announces acceptance of new drug application by China NMPA for Xerava for the treatment of complicated intra-abdominal infections

21 March 2021 - Everest Medicines announced today that the China National Medical Products Administration has accepted its new drug ...

Read more →

Antengene announces new drug application for ATG-010 (selinexor) granted priority review by China's NMPA

23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug ...

Read more →

The BCMA CAR-T co-developed by Innovent and IASO was granted breakthrough therapy designation by the NMPA for the treatment of relapsed/refractory multiple myeloma

22 February 2021 - Innovent Biologics today jointly announce that the Center for Drug Evaluation of China's National Medical Products Administration ...

Read more →

Junshi Biosciences announces acceptance by the NMPA of supplemental new drug application for toripalimab combined with chemotherapy for the first-line treatment of nasopharyngeal carcinoma

19 February 2021 - Third sNDA for toripalimab in China. ...

Read more →

Innovent and Lilly jointly announce the approval of Tyvyt (sintilimab) by China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for non-squamous non-small cell lung cancer

3 February 2021 - Innovent Biologics and Eli Lilly today jointly announced that the National Medical Products Administration of China has ...

Read more →